Search Results - "DeSilvio, Michelle L"

Randomized Trial of Lapatinib Versus Placebo Added to Paclitaxel in the Treatment of Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancer by Guan, Zhongzhen, Xu, Binghe, DeSilvio, Michelle L, Shen, Zhenzhou, Arpornwirat, Wichit, Tong, Zhongsheng, Lorvidhaya, Vicharn, Jiang, Zefei, Yang, Junlan, Makhson, Anatoly, Leung, Wai Lim, Russo, Mark W, Newstat, Beth, Wang, Li, Chen, George, Oliva, Cristina, Gomez, Henry

“…Lapatinib is an oral small-molecule tyrosine kinase inhibitor of both epidermal growth factor receptor and human epidermal growth factor receptor 2 (HER2)…”
Get full text

Phase II Study of Predictive Biomarker Profiles for Response Targeting Human Epidermal Growth Factor Receptor 2 (HER-2) in Advanced Inflammatory Breast Cancer With Lapatinib Monotherapy by JOHNSTON, Stephen, TRUDEAU, Maureen, HARRIS, Jennifer, WESTLUND, Ron E, SALAZAR, Vanessa, ZAKS, Tal Z, SPECTOR, Neil L, KAUFMAN, Bella, BOUSSEN, Hamouda, BLACKWELL, Kimberley, LORUSSO, Patricia, LOMBARDI, Donald P, AHMED, Slim Ben, CITRIN, Dennis L, DESILVIO, Michelle L

“…Inflammatory breast cancer (IBC) is one of the most aggressive forms of breast cancer. Lapatinib, an oral reversible inhibitor of epidermal growth factor…”
Get full text

Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05 by Feigenberg, Steven J, Lee, W Robert, Desilvio, Michelle L, Winter, Kathryn, Pisansky, Thomas M, Bruner, Deborah Watkins, Lawton, Colleen, Morton, Gerald, Baikadi, Madhava, Sandler, Howard

“…To prospectively assess health-related quality of life (HRQOL) during the first year after treatment with prostate brachytherapy (PB) alone for T1c-2a prostate…”
Get more information

Comparison of Conventional-Dose vs High-Dose Conformal Radiation Therapy in Clinically Localized Adenocarcinoma of the Prostate: A Randomized Controlled Trial by Zietman, Anthony L, DeSilvio, Michelle L, Slater, Jerry D, Rossi, Carl J, Miller, Daniel W, Adams, Judith A, Shipley, William U

“…CONTEXT Clinically localized prostate cancer is very prevalent among US men, but recurrence after treatment with conventional radiation therapy is common…”
Get full text

Measurement of Plasma-Derived Substance P: Biological, Methodological, and Statistical Considerations by Campbell, Donald E, Raftery, Nancy, Tustin, 3rd, Richard, Tustin, Nancy B, Desilvio, Michelle L, Cnaan, Avital, Aye, Pyone Pyone, Lackner, Andrew A, Douglas, Steven D

“…Classifications Services CVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen by Yardley, Denise A., Hart, Lowell, Bosserman, Linda, Salleh, Mansoor N., Waterhouse, David M., Hagan, Maura K., Richards, Paul, DeSilvio, Michelle L., Mahoney, Janine M., Nagarwala, Yasir

“…Lapatinib, an oral, reversible inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2 (HER2) tyrosine kinase, has proven…”
Get full text

Increasing external beam dose for T1-T2 prostate cancer: effect on risk groups by Thames, Howard D, Kuban, Deborah A, DeSilvio, Michelle L, Levy, Larry B, Horwitz, Eric M, Kupelian, Patrick A, Martinez, Alvaro A, Michalski, Jeff M, Pisansky, Thomas M, Sandler, Howard M, Shipley, William U, Zelefsky, Michael J, Zietman, Anthony L

“…The aim of this study was to investigate effect of increasing dose on risk groups for clinical failure (CF: local failure or distant failure or hormone…”
Get more information

Surrogate End Points for Prostate Cancer: What Is Prostate-Specific Antigen Telling Us? by Sandler, Howard M., DeSilvio, Michelle L.

“…Prostate cancer is a common malignancy. The observed incidence of prostate cancer has undergone dramatic changes because of the widespread use of…”
Get full text